secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beta Bionics, Inc. (BBNX)
CIK:        0001674632
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001171843-26-000145
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beta Bionics preliminary Q4 2025 net sales ≥$32M, up >56% YoY; installed base >35K
--------------------------------------------------------------------------------

- Net sales expected ≥$32.0M, up >56% from $20.4M in Q4 2024.
- DME channel net sales ≥$22.3M (+23% YoY); PBP channel ≥$9.7M (+308% YoY).
- Installed customer base ≥35,000 users (+128% YoY); new patient starts ≥5,581 (+36% YoY).
- ~69% of new starts from multiple daily injections; 25-30% are type 2 diabetes patients.
- Full Q4 and FY 2025 results to be reported Feb 17, 2026; conference call scheduled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674632/000117184326000145/0001171843-26-000145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674632/000117184326000145/f8k_010726.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer